公开(公告)号：US20240383922A1

公开(公告)日：2024-11-21

申请号：US18631866

申请日：2024-04-10

Applicant: Gilead Sciences, Inc.

Inventor： Wilian Augusto Cortopassi Coelho ,  Chaodi Dai ,  Katherine De La Fuente ,  Julie Farand ,  Juan A. Guerrero ,  Tezcan Guney ,  Hongyan Guo ,  Safaa S. Jamshed ,  Darryl Kato ,  Irene N. Kiburu ,  Scott E. Lazerwith ,  James B.C. Mack ,  Joshua L. Martin ,  Jessica L. McKinley ,  Jonathan William Medley ,  Hyung-Jung Pyun ,  Thomas P. Stratton ,  Rhiannon Thomas-Tran ,  Maoqun Tian ,  Vickie H. Tsui ,  William J. Watkins ,  Jie Xu ,  Adam D. Zajdlik ,  Jennifer R. Zhang

IPC: C07D519/00 ,  A61K31/553 ,  A61K45/06

Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

公开(公告)号：US11858918B2

公开(公告)日：2024-01-02

申请号：US17724212

申请日：2022-04-19

Applicant: Gilead Sciences, Inc.

Inventor： Megan K. Armstrong ,  James S. Cassidy ,  Elbert Chin ,  Chienhung Chou ,  Jeromy J. Cottell ,  Chao-I Hung ,  Kavoos Kolahdouzan ,  David W. Lin ,  Michael L. Mitchell ,  Ezra Roberts ,  Scott D. Schroeder ,  Nathan D. Shapiro ,  James G. Taylor ,  Rhiannon Thomas-Tran ,  Nathan E. Wright ,  Zheng-Yu Yang

IPC: C07D405/14 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  C07D401/08 ,  C07D401/10 ,  C07D401/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D493/08 ,  C07D493/10 ,  C07F9/6558

CPC classification number: C07D405/14 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/675 ,  C07D401/08 ,  C07D401/10 ,  C07D401/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D493/08 ,  C07D493/10 ,  C07F9/65586

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

公开(公告)号：US20210171499A1

公开(公告)日：2021-06-10

申请号：US17077729

申请日：2020-10-22

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Gediminas J. Brizgys ,  James S. Cassidy ,  Elbert Chin ,  Chienhung Chou ,  Jeromy J. Cottell ,  Michael Graupe ,  Chao-I Hung ,  Kavoos Kolahdouzan ,  Scott D. Schroeder ,  Nathan D. Shapiro ,  Daniel G. Shore ,  Suzanne M. Szewczyk ,  James G. Taylor ,  Rhiannon Thomas-Tran ,  Nathan E. Wright ,  Zheng-Yu Yang ,  Sheila M. Zipfel

IPC: C07D401/14 ,  C07D401/10 ,  C07D409/14 ,  C07D235/16 ,  C07D403/06 ,  C07D405/14 ,  C07D471/04 ,  C07D493/08 ,  A61K45/06

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

公开(公告)号：US12122764B2

公开(公告)日：2024-10-22

申请号：US18069028

申请日：2022-12-20

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Zhimin Du ,  Musong Kim ,  Rhiannon Thomas-Tran ,  Michael T. Tudesco ,  Chandrasekar Venkataramani

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.

公开(公告)号：US20230391747A1

公开(公告)日：2023-12-07

申请号：US18195767

申请日：2023-05-10

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Gediminas J. Brizgys ,  James S. Cassidy ,  Elbert Chin ,  Chienhung Chou ,  Jeromy J. Cottell ,  Michael Graupe ,  Chao-I Hung ,  Kavoos Kolahdouzan ,  Scott D. Schroeder ,  Nathan D. Shapiro ,  Daniel G. Shore ,  Suzanne M. Szewczyk ,  James G. Taylor ,  Rhiannon Thomas-Tran ,  Nathan E. Wright ,  Zheng-Yu Yang ,  Sheila M. Zipfel

IPC: C07D401/14 ,  A61K45/06 ,  C07D235/16 ,  C07D401/10 ,  C07D403/06 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  C07D493/08 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D401/14 ,  A61K45/06 ,  C07D235/16 ,  C07D401/10 ,  C07D403/06 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  C07D493/08 ,  C07D413/14 ,  C07D417/14

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

公开(公告)号：US20230242508A1

公开(公告)日：2023-08-03

申请号：US18069028

申请日：2022-12-20

Applicant: Gilead Sciences, Inc.

Inventor： Peter A. Blomgren ,  Zhimin Du ,  Musong Kim ,  Rhiannon Thomas-Tran ,  Michael T. Tudesco ,  Chandrasekar Venkataramani

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zink Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

公开(公告)号：US20220288030A1

公开(公告)日：2022-09-15

申请号：US17159485

申请日：2021-01-27

Applicant: Gilead Sciences, Inc.

Inventor： Stephen E. Ammann ,  Gediminas J. Brizgys ,  James S. Cassidy ,  Elbert Chin ,  Chienhung Chou ,  Jeromy J. Cottell ,  Chao-I Hung ,  Kavoos Kolahdouzan ,  Daniel G. Shore ,  Suzanne M. Szewczyk ,  James G. Taylor ,  Rhiannon Thomas-Tran ,  Nathan E. Wright ,  Zheng-Yu Yang

IPC: A61K31/4184 ,  A61K45/06 ,  C07D405/10 ,  C07D405/14 ,  C07D409/14 ,  C07D413/10 ,  C07D498/04 ,  C07D471/04 ,  C07D493/04 ,  C07D493/10 ,  A61K31/424 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4439 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

公开(公告)号：US12091404B2

公开(公告)日：2024-09-17

申请号：US17690889

申请日：2022-03-09

Applicant: Gilead Sciences, Inc.

Inventor： Gediminas J. Brizgys ,  Chienhung Chou ,  Jeromy J. Cottell ,  Chao-I Hung ,  Michael L. Mitchell ,  James G. Taylor ,  Rhiannon Thomas-Tran ,  Nathan E. Wright ,  Zheng-Yu Yang ,  Sheila M. Zipfel

IPC: A61K31/4545 ,  A61K31/4439 ,  A61K45/06 ,  A61P1/16 ,  C07D211/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

CPC classification number: C07D409/14 ,  A61K31/4545 ,  A61K45/06 ,  A61P1/16 ,  C07D405/14 ,  C07D417/14 ,  C07D211/14

Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

公开(公告)号：US20240124412A1

公开(公告)日：2024-04-18

申请号：US18068700

申请日：2022-12-20

Applicant: Gilead Sciences, Inc.

Inventor： Gayatri Balan ,  Peter A. Blomgren ,  Julian A. Codelli ,  Zhimin Du ,  Musong Kim ,  Rhiannon Thomas-Tran ,  Michael T. Tudesco ,  Chandrasekar Venkataramani

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/14

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.

公开(公告)号：US20230373950A1

公开(公告)日：2023-11-23

申请号：US18184335

申请日：2023-03-15

Applicant: Gilead Sciences, Inc.

Inventor： Gayatri Balan ,  Peter A. Blomgren ,  Chen Chen ,  Julian A. Codelli ,  Zhimin Du ,  Musong Kim ,  Dorothée Saddier Axe ,  Gregg M. Schwarzwalder ,  Rhiannon Thomas-Tran ,  Michael T. Tudesco ,  Chandrasekar Venkataramani ,  William J. Watkins ,  Brian M. Weist ,  Suet C. Yeung ,  Helen Yu

IPC: C07D401/04

CPC classification number: C07D401/04 ,  C07B2200/05

Abstract: The present disclosure relates generally to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios) and/or IKZF4 (Eos). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2 and/or IKZF4, including cancer.